GoldenGolden
Advanced Search
DIOSynVax

DIOSynVax

A biotechnology company that has developed technology to expedite vaccine development. It was founded in 2017 and is located in Cambridge, the United Kingdom.

Company

DIOSynVax is a Cambridge-based company with a focus on developing technology to accelerate the development of vaccines for illnesses. Its name stands for Digitally designed, Immune Optimized Selected and Synthesized Vaccines. It is supported by Cambridge Enterprise, which is the commercialization arm of the University of Cambridge. The company states that the new technology will accelerate vaccine development and achieve improvements to the protection against emerging and re-emerging pathogens such as influenza, COVID-19, and viral hemorrhagic fevers.

COVID-19

During the COVID-19 pandemic in 2020, the company conducted research to understand the genetic make-up of the virus. It intends to use a combination of artificial intelligence and synthetic biology to develop a vaccine for COVID-19.

Timeline

People

Name
Role
LinkedIn

Dr. Jonathan Heeney

CEO

Dr. Rebecca Kinsley

COO

Further reading

Title
Author
Link
Type
Date

Cambridge University spin-out working on COVID-19 vaccine seeks Big Pharma alliance | Business Weekly | Technology News | Business news | Cambridge and the East of England

Tony Quested

Web

March 17, 2020

The race for a COVID-19 vaccine

Éanna Kelly

Web

Documentaries, videos and podcasts

Title
Date
Link

Behind the scenes at the lab developing coronavirus vaccine

March 17, 2020

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.